Published in Cell Microbiol on April 01, 2007
Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog (2007) 1.93
Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology (2007) 1.19
Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience. Curr Opin Virol (2011) 1.09
TLR/NCR/KIR: Which One to Use and When? Front Immunol (2014) 1.03
Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ (2015) 1.00
Filovirus vaccines. Hum Vaccin (2011) 0.98
Here today--not gone tomorrow: roles for activating receptors in sustaining NK cells during viral infections. Eur J Immunol (2010) 0.98
Structural basis for recognition of cellular and viral ligands by NK cell receptors. Front Immunol (2014) 0.94
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology (2013) 0.92
Correlates of immunity to filovirus infection. Viruses (2011) 0.91
Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J Immunol (2008) 0.87
The structural basis of ligand recognition by natural killer cell receptors. J Biomed Biotechnol (2011) 0.87
Natural killer cells in immunodefense against infective agents. Expert Rev Anti Infect Ther (2008) 0.86
Structural insights into activation of antiviral NK cell responses. Immunol Rev (2012) 0.85
Roles of natural killer cells in antiviral immunity. Curr Opin Virol (2015) 0.83
Evasion of natural killer cells by influenza virus. J Leukoc Biol (2010) 0.83
Evasion of the interferon-mediated antiviral response by filoviruses. Viruses (2010) 0.77
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
A Tn7-based broad-range bacterial cloning and expression system. Nat Methods (2005) 4.66
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med (2010) 3.25
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15
Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. Proc Natl Acad Sci U S A (2004) 2.86
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Rotavirus antigenaemia and viraemia: a common event? Lancet (2003) 2.51
Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect (2003) 2.48
Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement. Biosecur Bioterror (2006) 2.43
Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci U S A (2005) 2.35
In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A (2003) 2.32
Innate and adaptive immunity to Francisella. Ann N Y Acad Sci (2007) 2.32
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol (2009) 2.10
Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J (2012) 2.08
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Intracellular biology and virulence determinants of Francisella tularensis revealed by transcriptional profiling inside macrophages. Cell Microbiol (2009) 2.00
Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog (2012) 2.00
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis (2005) 1.82
The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov (2005) 1.79
Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol (2005) 1.78
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol (2008) 1.78
Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol (2005) 1.69
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. Antimicrob Agents Chemother (2009) 1.66
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol (2009) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol (2004) 1.58
Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun (2008) 1.56
3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A (2010) 1.52
Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol (2010) 1.48
Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem (2006) 1.47
Mechanical tension can specify axonal fate in hippocampal neurons. J Cell Biol (2002) 1.46
Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J Infect Dis (2004) 1.44
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine (2005) 1.44
Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis (2012) 1.40
IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol (2013) 1.39
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
Anthrax biosensor, protective antigen ion channel asymmetric blockade. J Biol Chem (2005) 1.37
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun (2003) 1.34
Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis (2008) 1.30
Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J (2007) 1.30
Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol (2007) 1.29
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog (2013) 1.28
Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol (2003) 1.27
Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother (2009) 1.26
Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci U S A (2010) 1.24
Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses (2012) 1.23
Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines (2008) 1.23
Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology (2010) 1.23
Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia. PLoS One (2012) 1.20
Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine (2004) 1.19